

Amendments to the Claims:

Please amend claim 94, and cancel claims 96-102 and 110 as follows:

1-93. (Canceled).

94. (Currently Amended) A method of identifying a functional analog of Ecteinasclidin-743 that inhibits drug-resistance which comprises:

- (a) providing a test compound;
- (b) determining whether said test compound inhibits SXR steroid and xenobiotic receptor (SXR) trans activation of an SXR target gene selected from the group consisting of mdrl and cyp3a4; and
- (c) if said test compound inhibits SXR trans activation of said SXR target gene, identifying said test compound as a functional analog of Ecteinasclidin-743 that inhibits drug resistance.

95. (Previously Presented) A method of claim 94 wherein said SXR target gene is mdrl.

96-102. (Canceled herein).

103. (Previously Presented) A method of claim 94 wherein said drug-resistance functional analog of Ecteinasclidin-743 inhibits the ability of SXR to trans activate mdrl gene transcription.

104. (Previously Presented) A method of claim 94 wherein said drug-resistance functional analog of Ecteinasclidin-743 is an SXR antagonist.

105. (Previously Presented) A method of claim 104 wherein said SXR antagonist prevents displacement of an SXR corepressor from SXR.

106. (Previously Presented) A method of claim 104 wherein said SXR antagonist prevents binding of an SXR ligand to the SXR ligand binding domain.

107. (Previously Presented) A method of claim 104 wherein said SXR antagonist inhibits interaction between SXR and an SXR coactivator.

108. (Previously Presented) A method of claim 107 wherein said SXR coactivator is selected from the group consisting of SRC1, ACTR, GRIP, PBP and an SXR coactivator mimetic peptide.

109. (Previously Presented) A method of claim 104 wherein said SXR antagonist is cytotoxic to tumor cells.

110. (Canceled herein).

111. (Previously Presented) A method of claim 94 wherein said determining whether said test compound inhibits SXR trans activation of an SXR target gene comprises:

- (a) providing test cells *in vitro*;
- (b) measuring the amount of expression of a reporter gene in said cells in the absence of said test compound;
- (c) adding said test compound to said cells;
- (d) measuring the amount of expression of said reporter gene in said cells in the presence of said test compound; and
- (e) determining whether the amount of expression of said reporter gene in said cells decreases with addition of said test compound to said cells,

wherein expression of said reporter gene is regulated by the functional association of the ligand binding domain of SXR with an SXR coactivator.